Published in World J Gastroenterol on January 07, 2008
Biliary complications in living liver donors. Surg Today (2010) 0.93
Anesthetic complications including two cases of postoperative respiratory depression in living liver donor surgery. J Anaesthesiol Clin Pharmacol (2011) 0.77
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg (2004) 55.13
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29
HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Calculation of child and adult standard liver volume for liver transplantation. Hepatology (1995) 3.33
Liver transplantation in children from living related donors. Surgical techniques and results. Ann Surg (1991) 3.32
Consensus statement on the live organ donor. JAMA (2000) 3.29
Liver transplantation from live donors. Lancet (1989) 2.98
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Reduced-sized orthotopic liver graft in hepatic transplantation in children. Surgery (1984) 2.63
Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation (1999) 2.61
Transplantation of liver grafts from living donors into adults--too much, too soon. N Engl J Med (2001) 2.61
Successful liver transplantation from a living donor to her son. N Engl J Med (1990) 2.58
A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation (2006) 2.55
The ethics of partial-liver donation. N Engl J Med (2002) 2.55
Ethics of liver transplantation with living donors. N Engl J Med (1989) 2.47
Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg (1997) 2.44
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants. Ann Surg (1990) 2.37
Body surface area and body weight predict total liver volume in Western adults. Liver Transpl (2002) 2.21
mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14
[Transplantation of a donor liver to 2 recipients (splitting transplantation)--a new method in the further development of segmental liver transplantation]. Langenbecks Arch Chir (1988) 2.02
Documented deaths of hepatic lobe donors for living donor liver transplantation. Liver Transpl (2006) 1.83
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Small-for-size partial liver graft in an adult recipient; a new transplant technique. Lancet (2002) 1.78
The first donor death after living-related liver transplantation in Japan. Transplantation (2004) 1.74
Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73
Whither living donor liver transplantation? Liver Transpl Surg (1999) 1.63
Liver transplantation using a right lobe graft from a living related donor. Transplantation (1994) 1.57
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg (2007) 1.56
Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review. Liver Transpl (2002) 1.52
Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg (1996) 1.51
Congestion of right liver graft in living donor liver transplantation. Transplantation (2001) 1.51
MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl (2003) 1.49
Successful living-related partial liver transplantation to an adult patient. Lancet (1994) 1.47
Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg (2002) 1.47
Long-term biological consequences of donor right hepatectomy including the middle hepatic vein in adult-to-adult live donor liver transplantation. Liver Transpl (2006) 1.46
Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.45
Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44
Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) (1984) 1.44
Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl (2001) 1.44
Evaluation of hepatic venous congestion: proposed indication criteria for hepatic vein reconstruction. Ann Surg (2002) 1.43
Safety and necessity of including the middle hepatic vein in the right lobe graft in adult-to-adult live donor liver transplantation. Ann Surg (2003) 1.32
Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl (2005) 1.27
Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Am J Transplant (2005) 1.26
Liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.24
Portal hyperperfusion injury as the cause of primary nonfunction in a small-for-size liver graft-successful treatment with splenic artery ligation. Liver Transpl (2003) 1.21
Allograft survival following adult-to-adult living donor liver transplantation. Am J Transplant (2004) 1.20
Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases. Ann Surg (2007) 1.19
Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl (2004) 1.18
Estimating liver weight of adults by body weight and gender. World J Gastroenterol (2006) 1.17
Living-donor liver transplantation: 12 years of experience in Asia. Transplantation (2003) 1.16
Liver transplantation in rats using small-for-size grafts: a study of hemodynamic and morphological changes. Arch Surg (2001) 1.15
Living related liver transplantation: 36 cases at the University of Hamburg. Transplant Proc (1994) 1.10
Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe graft. Transplantation (1997) 1.09
Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation (1996) 1.07
Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl (2004) 1.06
Living-donor liver transplantation for hepatocellular carcinoma. Transplantation (2003) 1.00
Right liver graft without middle hepatic vein reconstruction from a living donor. Transplantation (2002) 0.99
Operative outcomes of adult-to-adult right lobe live donor liver transplantation: a comparative study with cadaveric whole-graft liver transplantation in a single center. Ann Surg (2006) 0.99
Living donor liver transplantation for fulminant hepatic failure. Transplantation (2000) 0.99
Live donor liver transplantation in adults. Transplantation (2006) 0.98
Living donor liver transplantation in Japan and Kyoto University: what can we learn? J Hepatol (2005) 0.97
Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation (2005) 0.96
Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol (2005) 0.95
Right lobe living donor liver transplantation-addressing the middle hepatic vein controversy. Ann Surg (2003) 0.94
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. Ann Surg (1992) 0.94
Determinants of hospital mortality of adult recipients of right lobe live donor liver transplantation. Ann Surg (2003) 0.92
Hepatic venoplasty in living-donor liver transplantation using right lobe graft with middle hepatic vein. Transplantation (2003) 0.91
Segmental liver transplantation from a living donor. J Pediatr Surg (1969) 0.91
Tailoring donor hepatectomy per segment 4 venous drainage in right lobe live donor liver transplantation. Liver Transpl (2004) 0.90
Ethical considerations and rationale of adult-to-adult living donor liver transplantation. Liver Transpl (2001) 0.89
Hepatic venoplasty in right lobe live donor liver transplantation. Liver Transpl (2003) 0.88
When is a patient too well and when is a patient too sick for a liver transplant? Liver Transpl (2004) 0.88
Living related liver transplantation. Surg Today (1992) 0.87
Role of liver transplantation in the treatment of hepatocellular carcinoma. Semin Surg Oncol (1993) 0.84
Impact of MELD on short-term and long-term outcome following liver transplantation: a European perspective. Eur J Gastroenterol Hepatol (2005) 0.82
Living donor liver transplantation with left liver graft. Am J Transplant (2004) 0.82
FK 409 ameliorates small-for-size liver graft injury by attenuation of portal hypertension and down-regulation of Egr-1 pathway. Ann Surg (2004) 0.81
"Prope" tolerance: induction, lymphocyte depletion with minimal maintenance. Transplantation (2005) 0.81
Continuous versus interrupted suture for end-to-end biliary anastomosis during liver transplantation gives equal results. Liver Transpl (2007) 0.81
Organ preservation: experience with University of Wisconsin solution and plans for the future. Clin Transplant (1990) 0.80
Living-donor liver transplantation for high-urgency situations. Transplantation (2003) 0.79
The mystique of organ transplantation. J Am Coll Surg (2005) 0.78
The "privileged" liver and hepatic tolerogenicity. Liver Transpl (2001) 0.78
Comparison of the results of liver transplantation for elective versus urgent indications. Transplant Proc (2003) 0.77
Death of a living liver donor from illicit drugs. Liver Transpl (2007) 0.76
Rapamycin: friend, foe, or misunderstood? Liver Transpl (2003) 0.76
Obstacles to brain death and organ transplantation in Japan. Lancet (1991) 0.76
Multifocal hepatocellular carcinoma in patients undergoing living-related liver transplantation. Hepatogastroenterology (2003) 0.76
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg (2013) 3.11
Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg (2006) 2.59
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Hematopoietic chimerism in liver transplantation patients and hematopoietic stem/progenitor cells in adult human liver. Hepatology (2012) 2.47
Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res (2006) 2.32
11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med (2013) 2.29
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol (2005) 2.19
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol (2007) 2.06
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg (2011) 2.05
Identification of local and circulating cancer stem cells in human liver cancer. Hepatology (2008) 2.02
Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg (2004) 1.99
Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. J Am Coll Surg (2005) 1.98
The national program for deceased organ donation in China. Transplantation (2013) 1.83
High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg (2011) 1.79
Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg (2002) 1.77
Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways. Liver Transpl (2007) 1.69
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology (2010) 1.66
Comparison of early endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the management of acute biliary pancreatitis: a prospective randomized study. Clin Gastroenterol Hepatol (2005) 1.66
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63
Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl (2007) 1.58
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
Working up donors for high-urgency and elective adult-to-adult live donor liver transplantation. Liver Transpl (2007) 1.54
External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann Surg (2007) 1.54
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg (2013) 1.51
Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open (2012) 1.50
Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl (2012) 1.49
Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int (2008) 1.46
Long-term biological consequences of donor right hepatectomy including the middle hepatic vein in adult-to-adult live donor liver transplantation. Liver Transpl (2006) 1.46
Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg (2002) 1.45
Paired donor interchange to avoid ABO-incompatible living donor liver transplantation. Liver Transpl (2010) 1.45
Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma. Am J Gastroenterol (2004) 1.45
Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology (2008) 1.44
Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol (2005) 1.41
DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem (2011) 1.40
Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg (2007) 1.38
Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology (2010) 1.34
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol (2007) 1.31
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res (2005) 1.29
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg (2003) 1.27
Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res (2006) 1.25
Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg (2004) 1.24
Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg (2002) 1.23
Liver transplantation for acute-on-chronic liver failure. Hepatol Int (2009) 1.23
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology (2006) 1.20
Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases. Ann Surg (2007) 1.19
Estimating liver weight of adults by body weight and gender. World J Gastroenterol (2006) 1.17
An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res (2009) 1.16
Risk factors for biliary complications after liver transplantation. Arch Surg (2004) 1.16
Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res (2005) 1.15
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res (2005) 1.15
Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res (2010) 1.15
Increasing the recipient benefit/donor risk ratio by lowering the graft size requirement for living donor liver transplantation. Liver Transpl (2012) 1.14
Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction. Biochem Biophys Res Commun (2004) 1.13
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl (2005) 1.10
Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res (2004) 1.09
Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol (2004) 1.08
Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One (2012) 1.08
Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res (2005) 1.07
Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg (2014) 1.07
Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl (2004) 1.06
The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg (2008) 1.05
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist (2011) 1.05
PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene (2004) 1.05
Hepatic resection for incidentaloma. J Gastrointest Surg (2004) 1.04
Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res (2002) 1.04
Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl (2011) 1.04
Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. Arch Surg (2007) 1.04
Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg (2007) 1.04
ATR dependent activation of Chk2. J Cell Physiol (2006) 1.03
Comparison of systemic responses of radiofrequency ablation, cryotherapy, and surgical resection in a porcine liver model. Ann Surg Oncol (2004) 1.03
Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol Carcinog (2007) 1.03
FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant (2005) 1.03
HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics (2013) 1.02
Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement. World J Surg (2004) 1.02
Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther (2005) 1.02
Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res (2006) 1.02
A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes. Ann Surg (2008) 1.02
Management of carcinoma of the gallbladder: a single-institution experience in 16 years. J Surg Oncol (2008) 1.01
Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res (2004) 1.01
Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer (2011) 1.01
Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis (2004) 1.01
Outpatient laparoscopic cholecystectomy in Hong Kong Chinese -- an outcome analysis. Asian J Surg (2004) 1.01
FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One (2012) 1.01
The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. Cancer (2009) 1.01
Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS One (2011) 1.00
Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest (2009) 1.00
Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression. Clin Cancer Res (2006) 0.99